Acquired thrombotic thrombocytopenic purpura
MONDO:0019740Acquired thrombotic thrombocytopenic purpura is the non-hereditary form of thrombotic thrombocytopenic purpura (TTP), characterized by profound peripheral thrombocytopenia, microangiopathic hemolytic anemia (MAHA) and single or multiple organ failure of variable severity.
Also known as: TTP, purpura, thrombotic thrombocytopenic, acquired ADAMTS13 deficiency, acquired TTP, acquired thrombotic thrombocytopenic purpura, autoimmune thrombotic thrombocytopenic purpura, Moschowitz syndrome, idiopathic thrombotic thrombocytopenic purpura
25 clinical trials for this condition and its sub-types, 13 tagged with Acquired thrombotic thrombocytopenic purpura itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug could keep rare blood disease in check
Disease control Recruiting nowThis pilot study tests efgartigimod, a drug that lowers harmful antibodies, in 15 adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare and life-threatening blood disorder. Participants receive weekly infusions for 8 weeks, then are monitored for another …
Phase 2 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for rare blood clotting disorder? daratumumab under study
Disease control Recruiting nowThis study is collecting information from 40 patients with a rare blood disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP) who have been treated with daratumumab. The goal is to see how well daratumumab works and how safe it is for patients whose disease d…
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Could a needle replace a machine? new study aims to simplify lifesaving iTTP treatment
Disease control Recruiting nowThis study tests whether a simpler treatment for immune thrombotic thrombocytopenic purpura (iTTP) works as well as the standard approach. Instead of daily plasma exchange (an invasive procedure), patients receive plasma infusions, immune-suppressing drugs, and caplacizumab. The …
Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Gene hunt: can DNA explain a rare blood disorder?
Knowledge-focused Recruiting nowThis study looks at whether a specific gene, TNFAIP3, is linked to immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare blood clotting disorder. Researchers will compare genetic data from 400 people with iTTP and healthy volunteers to see if gene variations affect d…
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Massive study aims to unlock secrets of rare blood disorder
Knowledge-focused Recruiting nowThis study reviews medical records from over 1,200 people with immune thrombotic thrombocytopenic purpura (iTTP), a rare and life-threatening blood disorder. The goal is to understand long-term health problems, such as heart disease and thinking issues, that survivors face. By an…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC